Changes in Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients With Relapsing Multiple Sclerosis in the FLUENT Study

被引：0
|
作者：
Mao-Draayer, Y. [1 ]
Cohen, J. A. [2 ]
Bar-Or, A. [3 ]
Han, M. H. [4 ]
Singer, B. [5 ]
Jaitly, N. [6 ]
Kolodny, S. [6 ]
Elam, C. [6 ]
Meng, X. [6 ]
Ziehn, M. [6 ]
Cree, B. A. [7 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Stanford Univ, Stanford, CA USA
[5] Missouri Baptist Med Ctr, St Louis, MO USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] UCSF, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P053
引用
收藏
页码：40 / 41
页数：2
相关论文
共 50 条
  • [21] Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study
    Mao-Draayer, Yang
    Cohen, Jeffrey A.
    Bar-Or, Amit
    Han, May H.
    Singer, Barry
    Williams, Ian M.
    Meng, Xiangyi
    Elam, Chelsea
    Weiss, Jamie L.
    Cox, Gina Mavrikis
    Ziehn, Marina
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2022, 8 (03)
  • [22] Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis
    Chin, P. S.
    Calabresi, P. A.
    Zhang, Y.
    von Rosenstiel, P.
    Kappos, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 187 - 187
  • [23] Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
    Ticha, Veronika
    Kodym, Roman
    Pocikova, Zuzana
    Kadlecova, Pavla
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 175 - 186
  • [24] Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
    Veronika Tichá
    Roman Kodým
    Zuzana Počíková
    Pavla Kadlecová
    [J]. Clinical Drug Investigation, 2017, 37 : 175 - 186
  • [25] Leprosy in two patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod
    Balasa, Alfred
    Hutton, George
    [J]. NEUROLOGY, 2019, 92 (15)
  • [26] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    [J]. BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [27] The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis
    Yang, Ting
    Tian, Xin
    Chen, Chao-Yang
    Ma, Ling-Yun
    Zhou, Shuang
    Li, Min
    Wu, Ye
    Zhou, Ying
    Cui, Yi-Min
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (04) : 637 - 645
  • [28] Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
    Murgia, Federica
    Lorefice, Lorena
    Noto, Antonio
    Spada, Martina
    Frau, Jessica
    Fenu, Giuseppe
    Coghe, Giancarlo
    Gagliano, Antonella
    Atzori, Luigi
    Cocco, Eleonora
    [J]. METABOLITES, 2023, 13 (03)
  • [29] Health Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Fingolimod to Ozanimod
    Hersh, C. M.
    Paul, D.
    Wang, C.
    Poul, R.
    Khaychuk, V.
    Thorpe, A.
    Chaudhry, B.
    Reardon, J.
    Conway, D. S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 198 - 199
  • [30] Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients
    Cannizzaro, Miryam
    Ferre, Laura
    Clarelli, Ferdinando
    Giordano, Antonino
    Sangalli, Francesca
    Colombo, Bruno
    Comi, Giancarlo
    Moiola, Lucia
    Martinelli, Vittorio
    Filippi, Massimo
    Esposito, Federica
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (10) : 5596 - 5605
12345